
    
      [Double Blind Phase] The primary objective is to compare change in the Average Daily Pain
      Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain
      (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo.

      [Open Extension Phase] The objective is to assess the long-term safety and efficacy of
      mirogabalin in participants with central neuropathic pain (central neuropathic pain after
      spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's
      disease).
    
  